Vascular impairment as a pathological mechanism underlying long-lasting cognitive dysfunction after pediatric traumatic brain injury.
Neurochemistry International. 2017-12-01; 111: 93-102
DOI: 10.1016/j.neuint.2017.03.022
Lire sur PubMed
1. Neurochem Int. 2017 Dec;111:93-102. doi: 10.1016/j.neuint.2017.03.022. Epub 2017
Apr 1.
Vascular impairment as a pathological mechanism underlying long-lasting cognitive
dysfunction after pediatric traumatic brain injury.
Ichkova A(1), Rodriguez-Grande B(1), Bar C(2), Villega F(3), Konsman JP(1),
Badaut J(4).
Author information:
(1)CNRS UMR 5287, INCIA, University of Bordeaux, France.
(2)CNRS UMR 5287, INCIA, University of Bordeaux, France; Department of Pediatric
Neurology, University Children’s Hospital of Bordeaux, France.
(3)Department of Pediatric Neurology, University Children’s Hospital of Bordeaux,
France.
(4)CNRS UMR 5287, INCIA, University of Bordeaux, France; Department of Basic
Sciences, Loma Linda University School of Medicine, Loma Linda, CA, USA.
Electronic address: .
Traumatic brain injury (TBI) is the leading cause of death and disability in
children. Indeed, the acute mechanical injury often evolves to a chronic brain
disorder with long-term cognitive, emotional and social dysfunction even in the
case of mild TBI. Contrary to the commonly held idea that children show better
recovery from injuries than adults, pediatric TBI patients actually have worse
outcome than adults for the same injury severity. Acute trauma to the young brain
likely interferes with the fine-tuned developmental processes and may give rise
to long-lasting consequences on brain’s function. This review will focus on
cerebrovascular dysfunction as an important early event that may lead to
long-term phenotypic changes in the brain after pediatric TBI. These, in turn may
be associated with accelerated brain aging and cognitive dysfunction. Finally,
since no effective treatments are currently available, understanding the unique
pathophysiological mechanisms of pediatric TBI is crucial for the development of
new therapeutic options.
Copyright © 2017 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.neuint.2017.03.022
PMID: 28377126 [Indexed for MEDLINE]